Clinical Trial Update: A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describes a Phase 1/2 study of SHR-A2102 combined with Adebrelimab, with or without other anti-tumor therapies, in recurrent/metastatic he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A2102

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING